Increased serum levels of advanced glycation end-products and diabetic complications

Diabetes Research and Clinical Practice

Volumn 41, Issue 2, 1998, Pages 131-137

  Ono, Yuri ^a   Aoki, Shin ^a   Ohnishi, Katsunori ^a   Yasuda, Takuzi ^a   Katsumi Kawano, ^b   Tsukada, Yutaka ^b  

^a Sapporo Shakaihoken Gen H ^*  (Japan)

^b SRL INC   (Japan)

Author keywords

Advanced glycation end product (AGE); Blood sugar control; Diabetic complications; Diabetic retinopathy; Renal function

Indexed keywords

GLUCOSE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCATION; HUMAN; HYPERGLYCEMIA; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RETINOPATHY;

AGED; BLOOD UREA NITROGEN; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED;

EID: 0032143589     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(98)00074-6     Document Type: Article

References (15)

1. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complication. New Engl. J. Med. 318:1988;1315-1321.
2. Monnier V.M. Nonenzymatic glycosylation, the Maillard reaction and the aging process. J. Gerontol. 45:1990;B105-B111.
3. Miyata S., Monnier V.M. Immunohistochemical detection of advanced glycosylation end products in diabetic tissue using monoclonal antibody to pyrraline. J. Clin. Invest. 89:1992;1102-1112.
4. Nicholls K., Mandel T.E. Advanced glycosylation endproducts in experimental murine diabetic nephropathy. Lab. Invest. 60:1989;486-491.
5. Vlassara H., Brownlee M., Cerami A. Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus. Proc. Natl. Acad. Sci. USA. 78:1981;5190-5192.
6. Makita Z., Radoff S., Rayfield E.J.et al. Advanced glycosylation end products in patients with diabetic nephropathy. New Engl. J. Med. 325:1991;836-842.
7. The Diabetes Control and Complication Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl. J. Med. 329:1993;977-986.
8. Nakayama H., Mitsuhashi T., Kuwajima S.et al. Immunochemical detection of advanced glycation end products in lens crystalline from streptozocin-induced diabetic rat. Diabetes. 42:1993;345-350.
9. Yamada K., Miyahara Y., Hamaguchi K.et al. Immunohistochemical study of human advanced glycosylation endproducts (AGE) in chronic renal failure. Clin. Nephrol. 42:1994;354-361.
10. Hasegawa G., Nakano K., Sawada M.et al. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int. 40:1991;1007-1012.
11. Makino H., Shikata K., Hironaka K.et al. Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy. Kidney Int. 48:1995;517-526.
12. Vlassara H., Striker L.J., Teichberg S., Fuh H., Ming Li Y., Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc. Natl. Acad. Sci. USA. 91:1994;11704-11708.
13. Yang C.W., Vlassara H., Peten E., He C., Striker G.E., Striker L.J. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc. Natl. Acad. Sci. USA. 91:1994;9436-9440.
14. Doi T., Vlassara H., Kirstein M., Yamada Y., Striker G.E., Striker L.J. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylated end products is mediated via platelet-derived growth factor. Proc. Natl. Acad. Sci. USA. 89:1992;2873-2877.
15. Makita Z., Vlassara H., Rayfield E.et al. Hemoglobin-AGE: A circulating marker of advanced glycosylation. Science. 258:1992;651-653.